Print Page  Close Window

Corporate Profile

Cidara is a clinical-stage biotechnology company focused on developing new anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. The company is currently advancing its novel echinocandin antifungal, CD101 IV, through Phase 2 and developing CD201, its bispecific antimicrobial immunotherapy, for the treatment of multi-drug resistant Gram-negative bacterial infections. CD101 IV has enhanced potency and is the only once-weekly therapy intended for the treatment and prevention of life-threatening invasive fungal infections. CD201 is the first drug candidate selected from Cidara’s novel Cloudbreak™ platform, the first immunotherapy discovery platform designed specifically to create compounds that direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens. Cidara is headquartered in San Diego, California.


Download Documentation Corporate Presentation May 2017
Download Documentation Analyst Day Presentation

Stock Information

CDTX (Common Stock)
PriceChange% ChangeVolume
$6.90 - 0.050.72%21,695
Previous CloseToday's OpenIntraday HighIntraday Low
Exchange: NASDAQ (US Dollar)
09/19/17 4:00 p.m. ET
Refresh quote


Stock chart for: CDTX.O.  Currently trading at $6.90 with a 52 week high of $12.95 and a 52 week low of $5.60.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources